Start-up gains $30M in Series A funds

With human trials for an experimental Alzheimer's therapy looming, San Diego-based Sonexa Therapeutics has closed its first round of venture funds with $30 million in the bag. Domain Associates, Scale Venture Partners and Alta Partners led the round. Sonexa says that it licensed a development compound to most world markets from a Japanese company. According to the release, the Sonexa team includes president and CMO Sharon Rogers, Ph.D., "who played a leading role in developing Aricept, the top-selling Alzheimer's medication."

- check out the press release

ALSO: Check out the top 20 VC deals of 2007. Report

Suggested Articles

Levo Therapeutics’ lead program did not beat placebo in a phase 3 study of Prader-Willi syndrome, a genetic disorder that causes insatiable hunger.

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.